Health Care·Pharmaceuticals·$119.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.00 | N/A | +4.82% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.00 | N/A | +4.82% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism about their product pipeline and future prospects. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted the strength of their pipeline despite not providing specific guidance.
They acknowledged ongoing challenges in the market but expressed confidence in future growth.
Bristol Myers Squibb's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 3.0%. This decline may reflect investor concerns about the lack of revenue details and future guidance, which could lead to uncertainty in the stock's performance moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KIMBERLY CLARK CORP
Oct 25, 2021